InventisBio Co (SHSE:688382) Change In Receivables : ¥0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is InventisBio Co Change In Receivables?

InventisBio Co's change in receivables for the quarter that ended in Mar. 2025 was ¥0.0 Mil. It means InventisBio Co's Accounts Receivable stayed the same from Dec. 2024 to Mar. 2025 .

InventisBio Co's change in receivables for the fiscal year that ended in Dec. 2024 was ¥14.0 Mil. It means InventisBio Co's Accounts Receivable declined by ¥14.0 Mil from Dec. 2023 to Dec. 2024 .

InventisBio Co's Accounts Receivable for the quarter that ended in Mar. 2025 was ¥173.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. InventisBio Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 1,934.29.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. InventisBio Co's liquidation value for the three months ended in Mar. 2025 was ¥1,659.8 Mil.

InventisBio Co Change In Receivables Historical Data

The historical data trend for InventisBio Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InventisBio Co Change In Receivables Chart

InventisBio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-1.50

-0.96

-32.68

-164.16

13.96

InventisBio Co Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

InventisBio Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.0 Mil.

InventisBio Co (SHSE:688382) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

InventisBio Co's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	173.588	/	8.189	*	91
=	1,934.29

2. In Ben Graham's calculation of liquidation value, InventisBio Co's accounts receivable are only considered to be worth 75% of book value:

InventisBio Co's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1632.651	-	103.055	+	0.75 * 173.588	+	0.5 * 0
=	1,659.8

InventisBio Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of InventisBio Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

InventisBio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InventisBio Co Ltd (SHSE:688382) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 4, Lane 67, Li Bing Road, Room 210, Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

http://www.inventisbio.com

InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.

InventisBio Co Headlines

No Headlines